X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-529-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.50 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable
X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions
What is X4 Pharmaceuticals' stock symbol?
X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."
When is X4 Pharmaceuticals' next earnings date?
What price target have analysts set for XFOR?
8 analysts have issued twelve-month price targets for X4 Pharmaceuticals' stock. Their forecasts range from $20.00 to $27.00. On average, they anticipate X4 Pharmaceuticals' stock price to reach $23.00 in the next year. This suggests a possible upside of 112.4% from the stock's current price. View Analyst Price Targets for X4 Pharmaceuticals.
What is the consensus analysts' recommendation for X4 Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for X4 Pharmaceuticals.
Has X4 Pharmaceuticals been receiving favorable news coverage?
News stories about XFOR stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. X4 Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for X4 Pharmaceuticals.
Who are some of X4 Pharmaceuticals' key competitors?
Some companies that are related to X4 Pharmaceuticals include Scholar Rock (SRRK), Nantkwest (NK), Translate Bio (TBIO), Agenus (AGEN), Compugen (CGEN), Precision BioSciences (DTIL), Voyager Therapeutics (VYGR), PDL BioPharma (PDLI), Autolus Therapeutics (AUTL), Adaptimmune Therapeutics (ADAP), Harpoon Therapeutics (HARP), Cabaletta Bio (CABA), BioCryst Pharmaceuticals (BCRX), Cellular Biomedicine Group (CBMG) and Tcr2 Therapeutics (TCRR).
What other stocks do shareholders of X4 Pharmaceuticals own?
Who are X4 Pharmaceuticals' key executives?
X4 Pharmaceuticals' management team includes the folowing people:
- Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 48)
- Dr. Renato T. Skerlj Ph.D., Founder and Member of Scientific Advisory Board
- Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 39)
- Ms. Ronny Mosston, VP of HR
- Dr. Robert David Arbeit M.D., Sr. VP of Clinical Devel. and Translational Research (Age 71)
Who are X4 Pharmaceuticals' major shareholders?
X4 Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (13.23%), BVF Inc. IL (9.17%), EcoR1 Capital LLC (3.33%), New Leaf Venture Partners L.L.C. (2.69%), RA Capital Management L.P. (2.17%) and Geode Capital Management LLC (1.45%).
Which major investors are selling X4 Pharmaceuticals stock?
XFOR stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P..
Which major investors are buying X4 Pharmaceuticals stock?
XFOR stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, BVF Inc. IL, EcoR1 Capital LLC, Berylson Capital Partners LLC, Geode Capital Management LLC, Renaissance Technologies LLC, New Leaf Venture Partners L.L.C. and State Street Corp.
How do I buy shares of X4 Pharmaceuticals?
Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is X4 Pharmaceuticals' stock price today?
One share of XFOR stock can currently be purchased for approximately $10.83.
How big of a company is X4 Pharmaceuticals?
What is X4 Pharmaceuticals' official website?
How can I contact X4 Pharmaceuticals?
X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]
MarketBeat Community Rating for X4 Pharmaceuticals (NASDAQ XFOR)
MarketBeat's community ratings are surveys of what our community members think about X4 Pharmaceuticals and other stocks. Vote "Outperform" if you believe XFOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XFOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
